![Gunnar M. Páh](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gunnar M. Páh
Directeur/Membre du Conseil chez Corflow Therapeutics AG
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Martin T. Rothman | M | 75 |
Corflow Therapeutics AG
![]() Corflow Therapeutics AG Medical SpecialtiesHealth Technology Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz. | 8 ans |
Robert Schwartz | M | - |
Corflow Therapeutics AG
![]() Corflow Therapeutics AG Medical SpecialtiesHealth Technology Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz. | 8 ans |
Timothy Snyder | M | 58 |
Corflow Therapeutics AG
![]() Corflow Therapeutics AG Medical SpecialtiesHealth Technology Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz. | 6 ans |
Erik Amble | M | 72 |
Corflow Therapeutics AG
![]() Corflow Therapeutics AG Medical SpecialtiesHealth Technology Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Suisse | 4 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Gunnar M. Páh
- Réseau Personnel